(Date:5/22/2012)... The number of liver transplants in the United States ... Researchers said one reason for the decline is that ... and many of those livers end up being discarded ... attempt a transplant. Another reason livers are discarded is ... fatty liver disease, which is associated with metabolic syndrome ...
(Date:5/22/2012)... The enforcement of Law 42/2010, which extends the smoking ... in the percentage of smokers (from 40.3% to 35.3%) ... applies to men and women of all ages and ... pioneering study, carried out by the Society of Prevention ... Security professionals) analysed the consumption of tobacco in the ...
(Date:5/22/2012)... (HealthDay News) -- Certain gene variants linked to ... lower urinary tract symptoms, according to a new ... variant might protect against those symptoms, the study ... of Medicine at Northwestern University in Chicago identified ... risk in nearly 2,000 healthy, white men enrolled ...
(Date:5/22/2012)... psychiatrists attend their field,s largest annual meeting each year, ... report overwhelmingly on positive results. , That,s the ... Journal of Clinical Psychopharmacology by two young psychiatrists ... analyzed the presentations given at two recent meetings of ... presented at the 2009 and 2010 APA meetings that ...
(Date:5/22/2012)... have determined the genome sequences of a dozen ... to be resistant to vancomycin, an antibiotic of ... independently in each strain, and identified shared features ... acquire vancomycin resistance and evade human immune defenses. ... is a leading cause of hospital-acquired infections in ...
Breaking Medicine News(10 mins):Health News:U.S. Liver Transplants Declining 2Health News:5 percent of workers gave up smoking when the anti-tobacco law took effect 2Health News:Study Ties Genes to Lower Urinary Tract Symptoms, Prostate Cancer Risk 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 3Health News:Genomes show how Staph bacteria gain resistance to last-line drug 2... could help experts determine who,s lying and who,s telling ... They say the eyes are a window into the ... now that "microexpressions" -- lightning-fast, almost imperceptible facial expressions ... thinking. , Now, new research suggests that people have ...
... findings show a link between micronutrient supplementation and reduced ... study published in the June 1 issue of The ... assessment and support in tuberculosis therapy, once common before ... integral part of clinical therapy in most low-income countries ...
... SMBL ) will hold its annual meeting of ... at the Teaneck Marriott at Glenpointe, 100,Frank W. Burr ... close of business on April 2, 2008, are entitled ... before the meeting., About Smart Balance Inc., ...
... autism are increasingly turning to sensory integration treatment ... and theyre seeing good results. In 2007, 71 ... treatment used sensory integration methods, and 91 percent ... from Temple University researchers, presented this month at ...
... Load ... Delivery, SAN JOSE, Calif., April 25 A10 ... of plasma,products, vaccines and other biopharmaceuticals, selected and deployed,A10,s ... application,delivery platform for its MyFluVaccine(TM) portal. MyFluVaccine,(TM),delivered by FFF ...
... surgeons need to remove part of the pancreas, performing ... shorter hospital stay and fewer complications, researchers have concluded. ... remove pancreatic tumors and cysts over five years found ... time in the hospital without experiencing more complications such ...
Other Medicine News:Health News:Fleeting Facial Expressions Reveal Deep Secrets 2Health News:Fleeting Facial Expressions Reveal Deep Secrets 3Health News:Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence 2Health News:Autistic mannerisms reduced by sensory treatment 2Health News:Autistic mannerisms reduced by sensory treatment 3Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 2Health News:FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager 3(Date:5/22/2012)... NEW YORK, May 22, 2012 Fox Insurance Company, ... York, NY, announces the confirmation of a judgment in ... pharmacy benefit manager, in excess of $3.3 million, following ... negligence and breach of contract. On May 21, 2012, ... Georgia, Atlanta Division, issued its decision confirming the arbitration ...
(Date:5/22/2012)... MOUNTAIN VIEW, Calif., May 22, 2012 Based ... market, Frost & Sullivan recognizes Labcyte Inc. with ... for its Echo liquid handler. While various liquid ... incorporates the wide range of advantages provided by ... to revolutionize liquid handling, Labcyte developed a platform ...
(Date:5/22/2012)... Conn., May 22, 2012 Valeritas , ... a new, simple disposable device for the delivery ... 2 diabetes, has selected dLife to ... number-one resource and community network for people living ... V-Go Life, a comprehensive diabetes lifestyle management and ...
Breaking Medicine Technology:Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager 2Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 2Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 3Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 4Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 5Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device 2Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device 3Valeritas Inc. Selects dLife's New Diabetes Patient Engagement Solution For Valeritas' V-go Disposable Insulin Delivery Device 4Scripps scientists see the light in bizarre bioluminescent snail 16922 1Scripps scientists see the light in bizarre bioluminescent snail 16922 2Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A 623 Antheras Investigational Novel Peptibody Agent 13285 1Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A 623 Antheras Investigational Novel Peptibody Agent 13285 2Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A 623 Antheras Investigational Novel Peptibody Agent 13285 3Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A 623 Antheras Investigational Novel Peptibody Agent 13285 4Fighting flu in newborns begins in pregnancy 77841 1Fighting flu in newborns begins in pregnancy 77841 2... JMR-132 could provide a new therapeutic approach for ... CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... endocrine therapy and oncology, today presented an,abstract outlining ... antagonist JMR-132 in breast cancer, at the American,Association ...
... previously announced, primary endpoint not met; plausibly,confounded ... ERBITUX,-, NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ ... today,announced detailed results from the EPIC study ... - comparing ERBITUX(R),(Cetuximab) plus irinotecan to irinotecan ...
Other Medicine Technology:AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9... This increased magnification all glass (1.5x) ... details with more ease., The 4 mirror ... for static and dynamic gonioscopy and features ... high magnification to appreciate details previously unattainable ...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... P2000 Pachymeter [i.e., PalmScan P2000] device ... biometer, which incorporates A-mode pulsed-echo ultrasound,technology, ... accurately measure the corneal thickness (CT) ... PalmScan P2000 includes two software user,interfaces; ...
... A-Scan [i.e., PalmScan A2000] device is intended ... A-mode pulsed-echo ultrasound,technology, and thus may be ... (AL), anterior,chamber depth (ACD), and lens thickness ... is also intended for calculating the optical ...
Medicine Products:Biology NavigationMedical Navigation